Development Of A Diagnostic Test For Bipolar Disorder (BD)
Funder
National Health and Medical Research Council
Funding Amount
$140,330.00
Summary
A unique test that monitors the rate of switching between the hemispheres of the brain in response to visual stimuli has been devised. A patent application covers an apparatus and test to measure the switching rate between the hemispheres and the way in which such measurements can be used as a means to diagnose bipolar disorder (BD). BD, also called manic depression, is a form of depression that currently affects over six million people worldwide with about three million in the USA alone. The co ....A unique test that monitors the rate of switching between the hemispheres of the brain in response to visual stimuli has been devised. A patent application covers an apparatus and test to measure the switching rate between the hemispheres and the way in which such measurements can be used as a means to diagnose bipolar disorder (BD). BD, also called manic depression, is a form of depression that currently affects over six million people worldwide with about three million in the USA alone. The condition has phases of mania and depression and periods of remittance. Full cycles of BD can occur as many as three times a year and for many patients, this is a lifelong condition. BD is effectively treated, once it is diagnosed. It is estimated that 20% of sufferers go undiagnosed and many more are misdiagnosed. The cost of mis- or non-diagnosis is measured by suicides, the financial burden on society with health care, loss of productivity etc, effects on family and associates, crime, etc. Diagnosis to date is achieved mainly by subjective means such as questionnaires. These instruments do not conclusively separate BD from other forms of depression and schizophrenia, for which treatment is quite different. Nor do they allow for factors such as substance abuse and other medical conditions that the patient may be suffering. BD is hereditary with the slow hemispheric switch rate being an indicator of the genetic trait. This phenomenon allows for an objective test for BD, even if an individual has not had an episode of BD. The slow switch allows relatively easy separation of a BD patient from those exhibiting symptoms that may have other causes.Read moreRead less
The Diagnosis, Biomarker Identification And Measurement Of Drug Efficacy In Mental Illness And Neurological Conditions.
Funder
National Health and Medical Research Council
Funding Amount
$119,050.00
Summary
Globally, 2 billion people suffer from a neuropsychiatric illness. The cost is more than US$2 trillion a year. Hampering early intervention is the current lack of definitive, quantitative techniques for diagnosis and measurement of treatment efficacy. This research will determine whether the disease fingerprints produced by a new technique, EVestG, are diagnostically unique (to schizophrenia, depression and Parkinson's disease) and sensitive to disease progression and treatment response.